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Sciences and ChinesAbstract An in vitro feasibility study of the use of poly(ethylene carbonate) (PEC) as a
biodegradable coating material for drug-eluting stents is reported, and the performance of PEC
is compared with that of poly(lactic-co-glycolic acid) (PLGA). Scanning electron microscopy
(SEM) images of PEC and PLGA discs after treatment with an alkaline KO2 solution as a
superoxide source showed that the PEC maintained its integrity whereas holes and small particles
appeared during the treatment of PLGA. Sirolimus and paclitaxel were loaded into PEC and
PLGA in order to study drug release performance. Attenuated total reﬂectance–infrared (ATR–
FTIR) spectroscopy of sirolimus, PEC and the sirolimus-loaded PEC coating showed that no
chemical reaction occurred between sirolimus and PEC. The results of atomic force microscopy
(AFM) revealed that the mean roughness (Ra) values of the bare metal stent (BMS) and the drug-
eluting stent (DES) were 2.3 nm and 1.0 nm, respectively. After balloon expansion experiments, no
delamination or destruction of the PEC coating was observed. The drug release proﬁle of sirolimus
was different from that of paclitaxel when PEC was employed as the drug carrier, and the releasels Research Society. Production and hosting by Elsevier Ltd. All rights reserved.
2.06.002
teel Research Institute, China
76 Xueyuan Nanlu, Haidian,
87216.
(S. Zhou).
tute of Materia Medica, Chinese
e Pharmaceutical Association.
Table 1 Physicochemical prope
Polymer Mn (kDa)a
PEC 107
PLGA 88
aNumber average molecular weig
bWeight average molecular weigh
cPolydispersity index.
dRatio of lactic acid:glycolic acid
eGlass transition temperature.
H. Bian et al.296curves of sirolimus were different when PEC and PLGA were used as drug carriers. All the
experimental results demonstrated that PEC was one of the best potential stent-coating materials.
& 2012 Chinese Materials Research Society. Production and hosting by Elsevier Ltd. All rights reserved.1. Introduction
Percutaneous coronary intervention (PCI) has become the
favored method to treat patients with coronary artery disease.
In the past thirty years there have been three revolutionary
advances in PCI. In the ﬁrst decade of its use (1977–87),
interventional cardiologists experimented with angioplasty
balloons. Although an artery can be opened successfully using
a balloon, in a small percentage of cases it was found that
the artery collapsed when the balloon was deﬂated. A second
problem soon became evident as well, in that 30–40% of all
coronary arteries closed up again after balloon angioplasty.
Over the following decade, several generations of bare metal
stents (BMS) were developed. The use of a BMS virtually
eliminated many of the complications of abrupt artery closure,
but some restenosis persisted—the percentage of restenosis of
treated arteries decreased from 30% to 60% for balloon
angioplasty to 10–30% for BMS [1]. The ﬁrst-generation of
drug-eluting stents (DES) with controlled release of sirolimus
(CypherTM) or paclitaxel (TaxusTM) from durable polymers
began a new era, and greatly reduced angiographic and clinical
measures of restenosis compared with BMS [2–4].
It is acknowledged that all medical devices and therapies
have limitations, but those associated with this innovative
technology were quickly recognized [5]. Restenosis still occurs,
and very late stent thrombosis is more common with ﬁrst-
generation DES than with BMS due to delayed healing and re-
endothelialisation. Although re-endothelialisation is multifac-
torial in cause, durable polymer surface coatings can play a
part [3,6,7]. To limit the exposure of the artery to the polymer,
DES programs now aim to either greatly reduce the amount of
polymer on the stent or use biodegradable polymers [8].
Biodegradable polymer DES offers controlled elution of the
active drug from the stent backbone by means of a biocom-
patible polymer coating which, after completion of its useful
function, slowly degrades to inert organic monomers, thereby
eliminating the risk associated with the long-term presence of
a durable polymer in the coronary vessel wall. Although Byrne
et al. [9] found that there was no signiﬁcant difference between
biodegradable polymer and permanent polymer DES in terms
of three-year outcomes, the possibility of biodegradable
polymers improving the long-term safety of drug-eluting stentsrties of the polymers.
Mw (kDa)b
278
141
ht.
t.
.has been noted by Holmes et al. [10]. Nevertheless, the
potential beneﬁts of biodegradable polymers should be eval-
uated with longer follow-up [11].
PEC is a rubber-like polymer which has been shown to have
good biodegradability and biocompatibility in vivo [12]. The
use of PEC as a stent coating giving controlled release of
paclitaxel in vitro was ﬁrst demonstrated [13] in 2007, and it
was concluded that PEC is a promising stent-coating material
due to its good biological, mechanical and biodegradation
properties. Here we report a further in vitro feasibility study of
the utility of PEC as a coating material for drug-eluting stents.
Bare 316 L stainless stents were covered directly by sirolimus-
incorporated PEC without using a non-biodegradable poly-
mer, such as poly(p-xylylene) (PPX), as a basecoat. Sirolimus
was chosen as the incorporated drug since it is known to be
effective in prevent the excessive proliferation of smooth
muscle cells in vessel walls.2. Experimental
2.1. Materials
PEC was kindly provided by the Changchun Institute of
Applied Chemistry, Chinese Academy of Sciences (Jilin,
China). PLGA was purchased from Jinan Dai Gang Biologi-
cal Engineering Co., Ltd (Shandong, China). Sirolimus was
obtained from Hangzhou Eastpro Pharmaceutical Technology
Co., Ltd. (Zhejiang, China), and had a purity of over 96%.
Paclitaxel was purchased from Kunming Wan Bao Biological
Technology Co., Ltd. (Yunnan, China). 316 L stainless steel
stents (15 mm in length, 2 mm in diameter) were provided by
Advanced Technology & Materials Co., Ltd. (Beijing, China).
Dichloromethane and acetonitrile were of analytical grade.
The properties of PEC and PLGA polymers used in this study
are summarized in Table 1.
2.2. Preparation
4 g of PEC or PLGA was completely dissolved in 20 mL of
dichloromethane, and the solution poured into a petri dish. In
order to prevent the formation of voids within the polymerPDIc Ratio (L:G)d Tg (1C)
e
2.6 19
1.6 1:1 25
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dichloromethane evaporation. After 72 h of solvent evapora-
tion, 10 mm 10 mm 0.2 mm discs were die-cut from the
thick polymer ﬁlm. The discs were dried for three days in a
drying chamber under reduced pressure at room temperature
until constant weight was obtained.
A solution of the polymer (PEC or PLGA) in dichloro-
methane (1% w/v) containing the drug (sirolimus or pacli-
taxel) with a speciﬁed concentration was sprayed onto the
316 L stainless steel stent struts using an automatic spray
coating method (SONO-TEK Stent Spraying System, USA) to
form a polymer matrix. In some cases, the matrix was
subsequently covered with a second polymer layer without
the drug. The mass of drug loaded and the thickness of the
coating were determined by the concentration of the solution
and the spraying time. Finally, the coated stent was dried
under vacuum for 2 day at room temperature.Fig. 1 1H NMR spectrum of PEC.2.3. Characterization
Molecular weights (Mw¼weight average molecular weight;
Mn¼number average molecular weight) and molecular weight
distribution (PDI¼polydispersity index) were determined by
gel permeation chromatography (Waters 515-410, Waters,
USA). The ratio of ethylene carbonate units to ether groups
in PEC was determined by nuclear magnetic resonance
(NMR) spectroscopy (Bruker AM 400, Bruker Corp.,
Germany), with deuterated chloroform as a solvent. The glass
transition temperature (Tg) was characterized using a differ-
ential scanning calorimeter (SDT 2960, TA Corp., USA).
Polymer samples were sealed in aluminum pans and heated
twice in a nitrogen atmosphere. Thermograms covering the
range from 40 to 190 1C were recorded at a heating and a
cooling rate of 10 1C per minute. The second run was used for
measurement of Tg. Tensile measurements were performed
using an extensometer (Model 1185, Instron, USA) with an
oven at 37 1C.
The morphologies of the coated stents and the surface of
the polymer discs were investigated by SEM (JEOL JSM-6390
SEM, JEOL Co., Ltd., Japan). Prior to SEM examination,
samples were sputter-coated with a gold layer under vacuum
for 30 s (SBC-2, KYKY Technology Development Ltd.,
China). The morphology and the mean roughness (Ra) of
the coatings were characterized by atomic force microscopy
(AFM) (Nanoscope IIIa, Digital Instruments, Veeco Metrol-
ogy Group, America). The PEC/sirolimus blend was also
characterized by attenuated total reﬂectance–Fourier trans-
form infrared (ATR–FTIR) spectroscopy (Model 750,
Nicolet, USA).
For in vitro drug release tests, a drug-loaded stent was
incubated in 2 mL of normal phosphate buffered saline (PBS,
0.05 M, pH 7.4), which was used to simulate an in vivo environ-
ment. The specimens were kept in a low speed self-balancing
centrifuge (BFX4-80, Baiyang Centrifuge Plant, China) at a speed
of 72 rpm at 37 1C. At deﬁned time intervals the buffer was
withdrawn and replaced by 2 mL of fresh medium. The 2 mL
release protocol was mixed with 3 mL of acetonitrile. The mixed
solution was centrifuged at 4000 rpm for 10 min, then 3 mL of
supernatant was taken out and ﬁltered through a 0.45 mm ﬁlter
membrane, and ﬁnally the amount of drug released was quantiﬁedby UV–vis spectrophotometry (UV-2102 PCS, Unico, USA). All
measurements were performed in triplicate to get average values.3. Results and discussion
3.1. 1H NMR spectroscopy
To determine whether PEC meet the demands for a pharma-
ceutical application or not, it is important to identify the
structural components affecting its biodegradability behavior.
PEC with a large molecular weight (278 kDa) was employed,
since previous studies [14] have shown that PEC with mole-
cular weight smaller than 130 kDa is resistant to biodegrada-
tion in vivo.
Fig. 1 shows the 1H NMR spectrum of the PEC. The
relative intensities of the signal at 4.37 ppm (Integral Ia) from
the ethylene carbonate units (ethylene units between two
carbonate functions) (–OOC–O–CH2–CH2–O–COO–), those
at 4.29 and 3.73 ppm (Integrals Ib and Ic) from ethylene units
between one carbonate and one ether function (–OOC–O–
CH2–CH2–O–) and that at ca. 3.65 ppm (Integral Id) from
ethylene units between two ether functions (–O–CH2–CH2–O–)
were determined. The ratio of ethylene carbonate units (ECU) to
ether functions (EF) and the IEF (incorporated ether function)
value can be calculated from the following formulae [14]:
½% of ECU¼ 100 Ia=ðIa þ Ib þ Ic þ IdÞ ¼ 82:54%
½% of EF¼ 100 ðIc þ IdÞ=ðIa þ Ib þ Ic þ IdÞ ¼ 14:18%
½% of IEF¼ 100 Ic=ðIa þ IcÞ ¼ 13:98%
The degradation time of PEC is usually less than 30 day
in vivo [12,15], whereas a longer time of degradation and drug
release is desirable for clinical application because coronary
restenosis and vascular smooth muscle cell proliferation and
migration often occur within 3–6 months after PCI [16,17].
In our case the IEF value of 13.98% is so large that the
degradation of PEC will have a lag time, which will effectively
lengthen the degradation time. In general, drug release from a
conventional non-degradable matrix involves an initial burst
with a fast rate, followed by a period of slower release. The
inﬂuence of the lag time may mean, however, that the rate of
H. Bian et al.298release of a drug from the PEC ﬁlm over time is more uniform
than for a typical matrix. This is because during the lag time
the drug release results only from dissipation, but an increase
in drug release after the onset of degradation should compen-
sate for the decrease in the rate of dissipation after the
initial burst.Fig. 2 SEM micrographs of PLGA and PEC discs: 100 times magniﬁ
(e) 200, and (g) 500 times magniﬁcation views of PLGA after degradati
views of PEC after degradation for three weeks.3.2. Degradation of the PEC ﬁlm
Biodegradation can be characterized by two surface-related
phenomena: bulk erosion and surface erosion. In the case of
bulk erosion, biodegradation proceeds throughout the poly-
mer matrix. As for the surface erosion, the biodegradationcation views of (a) PLGA and (b) PEC before degradation; (c) 27,
on for three weeks; (d) 100, (f) 200, and (h) 500 times magniﬁcation
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involves the former, whilst that of PEC involves the latter. To
understand the surface morphology, PLGA and PEC discs
were incubated in PBS (pH¼12) containing potassium super-
oxide, KO2 (170 mmol), because it has been shown that PEC is
degraded by superoxide radical anions [12,18,19], which are
mostly produced in vivo by inﬂammatory cells. The PBS was
replaced by fresh solution every day. After three weeks of
incubation, the discs were taken out and evacuated to constant
weight.
SEM micrographs of the PLGA and PEC discs before and
after incubation are shown in Fig. 2. In both cases, the initial
smooth surface was found to be porous after incubation for
three weeks. But holes and small particles appeared during the
treatment of PLGA, whereas the PEC disc maintained its
integrity better. It has been shown that particle shedding from
a stent coating causes increased vascular inﬂammation [20].3000 2500 2000 1500 1000
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Fig. 3 ATR–FTIR spectra of (a) sirolimus; (b) PEC; (c) sirolimus-
loaded PEC coating.
Fig. 4 (a) SEM image of BMS; (b) SEM image of DESThus, the PEC coating should be less likely to induce
inﬂammation and the formation of a thrombus than PLGA.
Furthermore, PEC is ﬁrst degraded into ethylene carbonate
(EC) which is not stable and decomposes, ultimately giving
harmless CO2 and H2O [18]. Both the degradation process
itself, and the degradation products of PEC, should have no
adverse affects when it is used as a coating material. There-
fore, the mechanism of surface degradation-controlled release
of PEC may provide the basis for ‘‘on demand’’ drug-eluting
stent coatings.3.3. ATR–FTIR spectra of sirolimus-loaded PEC coating
The ATR–FTIR spectra of sirolimus, PEC, and sirolimus-
incorporated PEC are shown in Fig. 3. The spectrum of
sirolimus (Fig. 3(a)) shows peaks at 3400, 2930, 1718 and
1634 cm1 which can be assigned to the stretching vibrations
of O–H, C–H, C¼O and C¼C respectively. The peaks at
1443 and 1376 cm1 are the asymmetric and symmetric C–H
bending vibration peaks, the peak at 1091 cm1 is character-
istic of C–N, and the peaks at 995 and 756 cm1 are the out-
of-plane vibration peaks of C¼C and C–H, respectively. The
spectrum of PEC (Fig. 3(b)) shows strong peaks at 1740 and
1218 cm1, which can be assigned to the C¼O and C–O–C
stretching vibrations, respectively. The spectrum of the siroli-
mus-loaded PEC coating (Fig. 3(c)) is a superposition of the
spectra of PEC and sirolimus showing that both are incorpo-
rated in the blend, with no chemical reaction occurring
between them.3.4. Morphology of PEC-coated and bare metal stents
The surface morphologies of a bare metal stent (BMS) and a
PEC-coated stent (DES) were characterized by SEM and
AFM, as illustrated in Fig. 4. SEM images showed that the; (c) AFM image of BMS; (d) AFM image of DES.
Fig. 5 SEM images of sirolimus-loaded PEC coated stent after
dilatation: (a) 50 times magniﬁcation; (b) 100 times magniﬁcation;
(c) 150 times magniﬁcation.
H. Bian et al.300surfaces of both BMS and DES were relatively smooth. The
values of the mean roughness (Ra) of BMS and DES, as
measured by AFM, were 2.3 nm and 1.0 nm respectively. The
smoother surface of the DES suggests that the pits and
scratches on the surface of BMS were ﬁlled up by the
sirolimus-incorporated PEC coating. For implants in direct
contact with blood, the surface roughness is an important
factor affecting the blood compatibility, since rough surfaces
increase the likelihood of blood clotting, whereas smooth
surfaces have a small area in contact with the blood, giving
better blood compatibility [21]. Thus, DES has a more
compatible surface than BMS.
3.5. Balloon dilatation experiments with DES
It is known that the stent exists in an expanded state after
implantation in the coronary artery. Polymeric coatings
should be resistant during implantation and expansion of
the stent. It is important that the integrity of the coating is
retained during stent crimping and implanting using balloon
catheters, because cracking or peeling of the coating may
cause severe (sub)acute thrombotic and inﬂammatory events,
even including abrupt vessel closure [22].
Balloon dilatation experiments were carried out with a
pressure of 15 MPa, which is greater than the clinical distend-
ing pressure of 10 MPa, to study the mechanical properties of
the PEC stent coating. SEM images of the sirolimus-loaded
PEC coated stent after dilatation (Fig. 5) show that the surface
remains smooth without any signs of disintegration or dela-
mination. The coating keeps integrated even near the bend of
the stent struts where are the mechanically stressed sites [23].
There are two factors which may contribute to the excellent
mechanical properties of the PEC coating. It is known that –
OH groups are formed on stainless steel substrates after
pickling [24] and these can form hydrogen bonds with the
carbonyl oxygen atom of the polycarbonate structure,
strengthening the binding between the polymer and the metal.
In addition, the glass transition temperature (Tg) of the
polymer has an important effect on the ﬂexibility of the stent
coating. The Tg of PEC is 19 1C. At 37 1C, PEC is in a rubbery
state with a tensile elongation of over 700%, which is an
important material property [25] and ensures that PEC will
not fracture during balloon dilatation experiments. Thus, the
present results indicate that the PEC coating can meet clinical
dilatation requirements.
3.6. Drug release kinetics curves
Sirolimus is the most prominent member of the group of inhibitors
of the mammalian target of rapamycin (mToR) [26]. mToR
inhibitors, such as sirolimus, also have antiproliferative and
antimigratory effects on vascular cell lines. Clinical evidence
suggests that cytostatic drugs, such as sirolimus, have a superior
outcome in terms of efﬁcacy and safety compared with cytotoxic
drugs, such as paclitaxel, when employed on a DES platform [27].
In the present study, the inﬂuence of sirolimus- and
paclitaxel-loaded PEC coatings on drug release proﬁles in
PBS was studied. The release curve in Fig. 6(a) illustrates that
the initial sirolimus release rate from a simple PEC carrier is
extremely fast. It is, therefore, necessary to coat a second layer
of drug-free polymer on top of the sirolimus-incorporatedPEC ﬁlm. The ratio of the thicknesses of the drug-loaded
polymer to the drug-free polymer was 2:1. The drug-free PEC
coating functioned as a diffusion barrier that provided a
controlled release of 60% of the drug within a time period
of 30 day (Fig. 6(b)). The release proﬁles in Fig. 6(c) and (d)
shows that the drug release of paclitaxel was not signiﬁcantly
affected by adding a drug-free polymer ﬁlm (the mass of drug
loaded and the thickness of both drug-loaded polymer and
drug-free polymer ﬁlms in (c) and (d) were the same as in (a)
and (b), respectively), and the rate of release was much slower
than for sirolimus. It is widely accepted that the preliminary
stage after stent implantation is critical as far as prevention
of vascular intimal injury and inﬂammation are concerned.
Thus, a sufﬁcient amount of sirolimus can be released in this
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Fig. 6 Sirolimus and paclitaxel release curves of PEC coated
stents: (1) sirolimus release curve in the absence of a drug-free
polymer coating; (2) sirolimus release curve with a drug-free
polymer coating, with the thickness of sirolimus coated polymer:-
drug-free polymer¼2:1; (3) paclitaxel release curve in the absence
of a drug-free polymer coating; (4) paclitaxel release curve with a
drug-free polymer coating, with the thickness of paclitaxel coated
polymer:drug free polymer¼2:1.
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Fig. 7 Sirolimus release proﬁles for PEC- and PLGA-coated
stents.
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insufﬁcient.
The inﬂuence of different polymers on the release behavior
of sirolimus was also examined. Fig. 7 shows drug release
kinetics for PEC and PLGA. A biphasic release proﬁle was
observed for PEC, with ca. 70% of the drug released rapidly
within the ﬁrst 20 day, followed by a much slower rate of
release. In the case of PLGA, an initial phase of rapid drug
release in the ﬁrst three days was followed, ﬁrst by a slow, and
ﬁnally a more rapid release, leading to a sigmoid liberation
proﬁle for sirolimus. The rate of drug release therefore clearly
depends on the polymer drug carrier. Thus, a sufﬁcient
amount of sirolimus can be released from the PEC coating
to meet clinical requirements.4. Conclusions(1) SEM images of PEC and PLGA after treatment with an
alkaline KO2 solution as a superoxide source show that
PEC retains its structural integrity while PLGA under-
goes signiﬁcant degradation. Thus, the surface erosion
characteristics of PEC are superior to the bulk erosion
characteristics of PLGA as a coating material. After
balloon expansion experiments up to a pressure of
15 MPa, no delamination or destruction of the PEC
coating was observed by SEM, which indicates that the
coating resists mechanical stress during stent expansion
and meets the clinical requirements for dilatation.(2) ATR–FTIR spectra of sirolimus, PEC and the sirolimus-
loaded PEC coating show that there is no chemical
reaction between sirolimus and PEC and the coating is
simply a blend of sirolimus and PEC. AFM shows that
the sirolimus-incorporated PEC coated stent has a more
biocompatible surface than a bare metal stent, as it is
much smoother. The drug release proﬁles of drug-eluting
stents depend on both the drug and its carrier. However,
the drug release behavior of each DES studied in this
work can extend for more than 50 day.(3) Apart from its controlled and site-speciﬁc drug elution,
good biocompatibility and resistance to degradation, the
PEC matrix has excellent mechanical properties in terms
of ﬂexibility and long lasting adherence to the stent
surface. This feasibility study under in vitro conditions
demonstrates that PEC has good application prospects
as a coating material for drug-eluting stents and merits
further investigation in vivo.Acknowledgments
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